Whom is following up on this? Who has updated the stroke strategy? Who has the stroke strategy? I somehow missed this when it came out a year ago.
http://www.ncbi.nlm.nih.gov/pubmed/24938836
Abstract
BACKGROUND AND PURPOSE:
Stroke
treatment is constrained by limited treatment windows and the clinical
inefficacy of agents that showed preclinical promise. Yet animal and
clinical data suggest considerable poststroke plasticity, which could
allow treatment with recovery-modulating agents. Memantine is a
well-tolerated N-methyl-D-aspartate glutamate receptor antagonist in
common use for Alzheimer disease.
METHODS:
Memantine,
30 mg/kg per day, or vehicle, was delivered chronically in drinking
water beginning >2 hours after photothrombotic stroke.
RESULTS:
Although
there was no difference in infarct size, behavior, or optical intrinsic
signal maps in the first 7 days after stroke, mice treated chronically
with memantine showed significant improvements in motor control,
measured by cylinder test and grid-walking performance, compared with
vehicle-treated animals. Optical intrinsic signal revealed an increased
area of forepaw sensory maps at 28 days after stroke. There was
decreased reactive astrogliosis and increased vascular density around
the infarcted cortex. Peri-infarct Western blots revealed increased
brain-derived neurotrophic factor and phosphorylated-tropomyosin-related
kinase-B receptor expression.
CONCLUSIONS:
Our
results suggest that memantine improves stroke outcomes in an
apparently non-neuroprotective manner involving increased brain-derived
neurotrophic factor signaling, reduced reactive astrogliosis, and
improved vascularization, associated with improved recovery of sensory
and motor cortical function. The clinical availability and tolerability
of memantine make it an attractive candidate for clinical translation.
No comments:
Post a Comment